Sutro Biopharma reports FY2023 revenue of $153.7M and $333.7M cash, runway into H2 2025

SUTRO BIOPHARMA, INC.

Revenue $153.7M in FY2023 vs $67.8M in FY2022, driven by Vaxcyte option exercise and collaborations.
Cash and investments $333.7M plus Vaxcyte stock valued at $41.9M, providing runway into H2 2025.
Total operating expenses $243.0M; R&D $180.4M, G&A $62.6M; includes stock-based comp $24.9M, D&A $6.8M.
Jane Chung promoted to President and COO; enrollment in REFRαME-O1 for PROC ongoing, Part 1 expected complete H1 2024.
Vaxcyte paid $50M for manufacturing rights option, with additional $25M due within six months and up to $60M milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SUTRO BIOPHARMA, INC. reported the year ended December 31, 2023 results: revenue $153.7 million.

Period: the year ended December 31, 2023
Revenue: $153.7 million
Result: reported results

Exact text from the filing

stock on the last trading day of each reporting period, with any non-operating, unrealized gains and losses recorded in Sutro’s statements of operations. Revenue Revenue was $153.7 million for the year ended December 31, 2023, as compared to $67.8 million for the same period in 2022, with the 2023 amount related principally to the Vaxcyte manufacturing rights

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-035948

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.